Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease.
about
Models that matter: white matter stroke modelsAngiotensin-converting enzyme is a modifier of hypertensive end organ damageInhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats.Effect of P2X4 and P2X7 receptor antagonism on the pressure diuresis relationship in rats.Dynamic expression of proteins associated with adventitial remodeling in adventitial fibroblasts from spontaneously hypertensive rats.AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high-salt diet.Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in CYP1A1-REN2 transgenic ratsActivation of thiazide-sensitive co-transport by angiotensin II in the cyp1a1-Ren2 hypertensive rat.Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.Effects of hydroxysafflor yellow A on proliferation and collagen synthesis of rat vascular adventitial fibroblasts induced by angiotensin II.Enhancement of renin and prorenin receptor in collecting duct of Cyp1a1-Ren2 rats may contribute to development and progression of malignant hypertension.Irreversible renal damage after transient renin-angiotensin system stimulation: involvement of an AT1-receptor mediated immune response.Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension.Of mice and models: improved animal models for biomedical research.Nuclear transfer in rodents.Renal functional responses to selective intrarenal renin inhibition in Cyp1a1-Ren2 transgenic rats with ANG II-dependent malignant hypertension.Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertensionHyperglycemia and renin-dependent hypertension synergize to model diabetic nephropathy.Conditional Expression of Human PPARδ and a Dominant Negative Variant of hPPARδ In VivoChronic direct renin inhibition with aliskiren prevents the development of hypertension in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent hypertension.New aspects of vascular remodelling: the involvement of all vascular cell types.Role of the adventitia in pulmonary vascular remodeling.Hypertension, kidney, and transgenics: a fresh perspective.On the Origin of Urinary Renin: A Translational Approach.Renal nitric oxide synthase and antioxidant preservation in Cyp1a1-Ren-2 transgenic rats with inducible malignant hypertension.Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review.The renin-angiotensin system as a primary cause of polyarteritis nodosa in rats.Exogenous and endogenous angiotensin-II decrease renal cortical oxygen tension in conscious rats by limiting renal blood flow.Prolactin alters blood pressure by modulating the activity of endothelial nitric oxide synthase.Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.Renal disease pathophysiology and treatment: contributions from the rat.Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems.The adventitia: Essential role in pulmonary vascular remodeling.Vascular structural and functional changes: their association with causality in hypertension: models, remodeling and relevance.Evidence for aldosterone-dependent growth of renal cell carcinoma.Hypertension fails to disrupt white matter integrity in young or aged Fisher (F44) Cyp1a1Ren2 transgenic ratsEpoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic ratsAntihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME.Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.
P2860
Q26829657-D8113420-F775-4541-B12A-8A2732EF1419Q28505768-CF2837FA-9147-4057-8CE1-1C20A3A0F688Q30384751-F51CC138-117E-419A-BE97-EFE5B1132EC8Q30447718-3A87028E-F5F1-493F-B0D9-8D1D752844E6Q33577591-4C3E8651-B05C-4436-BB94-C22A8422FFF9Q33893353-A72C3FE5-ABB8-4200-B2EE-36BC1E331FCCQ33903019-80930ACC-A7CA-4ECE-B989-DE3CED9FEA33Q34257435-281FAEC5-C87A-4198-91B6-20B984CBA494Q34280055-398AFEA2-74B9-4AEB-9161-8F64A8AD7087Q34371344-EE480C24-B127-41F9-A975-6AB7266BB375Q34599968-B714403F-134E-4D53-8953-ED3B6EBE6034Q34612453-561B8936-C898-4724-AAD2-351EDB03EF21Q34860887-9FE0017B-7B50-4A2A-91D2-EF6A665FD14AQ35016224-9968F247-16B1-4D30-9F74-3213E625778FQ35608956-96AFD3E8-2779-4832-80AB-8CB4E4CF8918Q35652065-0AA3EEC2-C958-4B57-B6D5-1ED4CE8FBB4BQ35652125-C389A921-0DD1-4D69-8B66-7F3B1BDFB9F7Q35804146-9053BBE3-E115-43B1-B986-8348117B62BCQ35884894-1B103288-A61B-437E-8CFF-C1D07BCC14C5Q35911362-7BC4456E-6157-4FA7-80B9-6876517B3FF7Q36127987-C12D5140-E90B-49C8-AB2E-8E8D6DF14A67Q36432232-70B2FAE4-E495-440A-881B-EAE0DEA9E5DDQ36443015-349FB9D6-1C45-4677-8D82-EF8F6C0F98B3Q36803651-5C27F2E4-3E66-4420-9A96-D16E611B0CADQ37172395-2732C839-CC24-45F2-867B-CA7126444098Q37242444-462D9F9B-974F-4ACF-BF79-460B99B0188EQ37310598-C47D0DED-2D33-469E-8FE2-79E37F033A74Q37382427-3D3E700B-892C-4C91-8570-9DF12749C36CQ37398164-5307EEE7-3171-4136-B5C7-8B201C3DAB04Q37430944-1D128B11-8812-4006-B52F-FCA25B347698Q37545416-76826283-DF61-4D69-B1CA-7C7CF0A84391Q37592161-3EAC14A5-4952-461D-8E26-F03E18EF3ABBQ38112032-35E8E4E7-B6FD-4789-B3D0-0AC73A3C8E09Q38991970-56D13D6C-F2F8-4369-AA75-537A56079431Q38997782-3A3084D2-A227-4FE7-B7DA-B0E193B9CFE5Q40515034-BE2030C4-C71C-4E50-A552-3C02B40166E3Q41648482-3CB39112-7218-4C31-976F-6E2DB2DD6CBFQ41774595-40994787-DCA9-4291-99E2-9BE7C42C32F9Q41832341-97904319-F7FE-4083-82DA-C5A241EA76F7Q42026998-EB8E236B-7863-4381-8530-EEEAD04456F7
P2860
Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Controlled hypertension, a tra ...... s underlying vascular disease.
@en
Controlled hypertension, a tra ...... s underlying vascular disease.
@nl
type
label
Controlled hypertension, a tra ...... s underlying vascular disease.
@en
Controlled hypertension, a tra ...... s underlying vascular disease.
@nl
prefLabel
Controlled hypertension, a tra ...... s underlying vascular disease.
@en
Controlled hypertension, a tra ...... s underlying vascular disease.
@nl
P2093
P2860
P356
P1476
Controlled hypertension, a tra ...... s underlying vascular disease.
@en
P2093
Kantachuvesiri S
Kotelevtsev Y
Mullins JJ
P2860
P304
36727-36733
P356
10.1074/JBC.M103296200
P407
P577
2001-07-11T00:00:00Z